FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients
The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) of Darzalex (daratumumab)…
Joana Carvalho, PhD, managing science editor — 
Articles by Joana Carvalho
Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma
Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated…
Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and…
Ninlaro Maintenance Therapy Prolongs and Boosts Treatment Benefits in Myeloma Patients, Study Says
Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an…
European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients
The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and…
CARsgen to Begin CT053 Clinical Testing in China for Heavily Treated Myeloma Patients
CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed…
FDA Raises Concerns on Safety, Tolerability of Potential Myeloma Therapy Selinexor
The U.S. Food and Drug Administration has raised concerns in its newly released briefing materials over the safety and tolerability of Karyopharm Therapeutics‘ lead compound …
Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show
Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time until disease progression in patients with smoldering multiple myeloma who were not yet experiencing any symptoms of…
Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows
Adding Darzalex (daratumumab) to the standard pre-transplant therapy for multiple myeloma significantly increased the number of patients showing no signs of cancer after…
Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma
Molecular Templates has partnered with Takeda to develop engineered toxin bodies (EBTs) — a next-generation immuno-oncology therapy that delivers toxic payloads to cancer cells — targeting the…